The Effect of Oral Nimodipine on Cerebral Metabolism and Hemodynamic Parameters in Patients Suffering Aneurysmal Subarachnoid Hemorrhage.
Journal
Journal of neurosurgical anesthesiology
ISSN: 1537-1921
Titre abrégé: J Neurosurg Anesthesiol
Pays: United States
ID NLM: 8910749
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
received:
07
01
2023
accepted:
19
06
2023
medline:
28
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
aheadofprint
Résumé
Nimodipine is routinely administered to aneurysmal subarachnoid hemorrhage patients to improve functional outcomes. Nimodipine can induce marked systemic hypotension, which might impair cerebral perfusion and brain metabolism. Twenty-seven aneurysmal subarachnoid hemorrhage patients having multimodality neuromonitoring and oral nimodipine treatment as standard of care were included in this retrospective study. Alterations in mean arterial blood pressure (MAP), cerebral perfusion pressure (CPP), brain tissue oxygen tension (pbtO2), and brain metabolism (cerebral microdialysis), were investigated up to 120 minutes after oral administration of nimodipine (60 mg or 30 mg), using mixed linear models. Three thousand four hundred twenty-five oral nimodipine administrations were investigated (126±59 administrations/patient). After 60 mg of oral nimodipine, there was an immediate statistically significant (but clinically irrelevant) drop in MAP (relative change, 0.97; P<0.001) and CPP (relative change: 0.97; P<0.001) compared with baseline, which lasted for the whole 120 minutes observation period (P<0.001). Subsequently, pbtO2 significantly decreased 50 minutes after administration (P=0.04) for the rest of the observation period; the maximum decrease was -0.6 mmHg after 100 minutes (P<0.001). None of the investigated cerebral metabolites (glucose, lactate, pyruvate, lactate/pyruvate ratio, glutamate, glycerol) changed after 60 mg nimodipine. Compared with 60 mg nimodipine, 30 mg induced a lower reduction in MAP (relative change, 1.01; P=0.02) and CPP (relative change, 1.01; P=0.03) but had similar effects on pbtO2 and cerebral metabolism (P>0.05). Oral nimodipine reduced MAP, which translated into a reduction in cerebral perfusion and oxygenation. However, these changes are unlikely to be clinically relevant, as the absolute changes were minimal and did not impact cerebral metabolism.
Identifiants
pubmed: 37501395
doi: 10.1097/ANA.0000000000000928
pii: 00008506-990000000-00074
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Lovelock CE, Rinkel GJE, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology. 2010;74:1494–1501. doi:10.1212/WNL.0b013e3181dd42b3
doi: 10.1212/WNL.0b013e3181dd42b3
Claassen J, Park S. Spontaneous subarachnoid haemorrhage. Lancet. 2022;400:846–862. doi:10.1016/S0140-6736(22)00938-2
doi: 10.1016/S0140-6736(22)00938-2
Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308:619–624. doi:10.1056/NEJM198303173081103
doi: 10.1056/NEJM198303173081103
Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636–642. doi:10.1136/bmj.298.6674.636
doi: 10.1136/bmj.298.6674.636
Velat GJ, Kimball MM, Mocco JD, et al. Vasospasm after aneurysmal subarachnoid hemorrhage: review of randomized controlled trials and meta-analyses in the literature. World Neurosurg. 2011;76:446–454. doi:10.1016/j.wneu.2011.02.030
doi: 10.1016/j.wneu.2011.02.030
Diringer MN, Zazulia AR. Aneurysmal subarachnoid hemorrhage: strategies for preventing vasospasm in the intensive care unit. Semin Respir Crit Care Med. 2017;38:760–767. doi:10.1055/s-0037-1607990
doi: 10.1055/s-0037-1607990
Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;3:CD000277. doi:10.1002/14651858.CD000277.pub3
doi: 10.1002/14651858.CD000277.pub3
Barker FG, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg. 1996;84:405–414. doi:10.3171/jns.1996.84.3.0405
doi: 10.3171/jns.1996.84.3.0405
Alborch E, Salom JB, Torregrosa G. Calcium channels in cerebral arteries. Pharmacol Ther. 1995;68:1–34. doi:10.1016/0163-7258(95)00025-9
doi: 10.1016/0163-7258(95)00025-9
Triggle DJ. L-type calcium channels. Curr Pharm Des. 2006;12:443–457. doi:10.2174/138161206775474503
doi: 10.2174/138161206775474503
Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68:505–517. doi:10.3171/jns.1988.68.4.0505
doi: 10.3171/jns.1988.68.4.0505
Grotenhuis JA, Bettag W, Fiebach BJ, et al. Intracarotid slow bolus injection of nimodipine during angiography for treatment of cerebral vasospasm after SAH. A preliminary report. J Neurosurg. 1984;61:231–240. doi:10.3171/jns.1984.61.2.0231
doi: 10.3171/jns.1984.61.2.0231
Ljunggren B, Brandt L, Säveland H, et al. Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg. 1984;61:864–873. doi:10.3171/jns.1984.61.5.0864
doi: 10.3171/jns.1984.61.5.0864
Espinosa F, Weir B, Overton T, et al. A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings. J Neurosurg. 1984;60:1167–1175. doi:10.3171/jns.1984.60.6.1167
doi: 10.3171/jns.1984.60.6.1167
Nosko M, Weir B, Krueger C, et al. Nimodipine and chronic vasospasm in monkeys: Part 1. Clinical and radiological findings. Neurosurgery. 1985;16:129–136. doi:10.1227/00006123-198502000-00001
doi: 10.1227/00006123-198502000-00001
Philippon J, Grob R, Dagreou F, et al. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir (Wien). 1986;82:110–114. doi:10.1007/BF01456369
doi: 10.1007/BF01456369
Bork K, Wurm F, Haller H, et al. Neuroprotective and neuroregenerative effects of nimodipine in a model system of neuronal differentiation and neurite outgrowth. Molecules. 2015;20:1003–1013. doi:10.3390/molecules20011003
doi: 10.3390/molecules20011003
Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10:44–58. doi:10.1038/nrneurol.2013.246
doi: 10.1038/nrneurol.2013.246
Choi HA, Ko SB, Chen H, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit Care. 2012;16:363–367. doi:10.1007/s12028-012-9670-8
doi: 10.1007/s12028-012-9670-8
Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs. 2005;65(Suppl 2):1–10. doi:10.2165/00003495-200565002-00002
doi: 10.2165/00003495-200565002-00002
Porchet F, Chioléro R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;137:62–69. doi:10.1007/BF02188783
doi: 10.1007/BF02188783
Schmidt JM, Ko SB, Helbok R, et al. Cerebral perfusion pressure thresholds for brain tissue hypoxia and metabolic crisis after poor-grade subarachnoid hemorrhage. Stroke. 2011;42:1351–1356. doi:10.1161/STROKEAHA.110.596874
doi: 10.1161/STROKEAHA.110.596874
Paľa A, Schick J, Klein M, et al. The influence of nimodipine and vasopressors on outcome in patients with delayed cerebral ischemia after spontaneous subarachnoid hemorrhage. J Neurosurg. 2019;132:1096–1104. doi:10.3171/2018.11.JNS182891
doi: 10.3171/2018.11.JNS182891
Sandow N, Diesing D, Sarrafzadeh A, et al. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25:29–39. doi:10.1007/s12028-015-0230-x
doi: 10.1007/s12028-015-0230-x
MacKenzie M, Gorman SK, Doucette S, et al. Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage. Can J Hosp Pharm. 2014;67:358–365. doi:10.4212/cjhp.v67i5.1390
doi: 10.4212/cjhp.v67i5.1390
Hernández-Durán S, Mielke D, Rohde V, et al. Does nimodipine interruption due to high catecholamine doses lead to a greater incidence of delayed cerebral ischemia in the setting of aneurysmal subarachnoid hemorrhage? World Neurosurg. 2019;132:e834–e840. doi:10.1016/j.wneu.2019.08.001
doi: 10.1016/j.wneu.2019.08.001
Kieninger M, Gruber M, Knott I, et al. Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage. Neurocrit Care. 2019;31:32–39. doi:10.1007/s12028-019-00676-w
doi: 10.1007/s12028-019-00676-w
Stiefel MF, Heuer GG, Abrahams JM, et al. The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage. J Neurosurg. 2004;101:594–599. doi:10.3171/jns.2004.101.4.0594
doi: 10.3171/jns.2004.101.4.0594
Hlatky R, Valadka AB, Goodman JC, et al. Patterns of energy substrates during ischemia measured in the brain by microdialysis. J Neurotrauma. 2004;21:894–906. doi:10.1089/0897715041526195
doi: 10.1089/0897715041526195
Nordström CH, Nielsen TH, Schalén W, et al. Biochemical indications of cerebral ischaemia and mitochondrial dysfunction in severe brain trauma analysed with regard to type of lesion. Acta Neurochir (Wien). 2016;158:1231–1240. doi:10.1007/s00701-016-2835-z
doi: 10.1007/s00701-016-2835-z
Hosmann A, Milivojev N, Dumitrescu S, et al. Cerebral nitric oxide and mitochondrial function in patients suffering aneurysmal subarachnoid hemorrhage-a translational approach. Acta Neurochir (Wien). 2021;163:139–149. doi:10.1007/s00701-020-04536-x
doi: 10.1007/s00701-020-04536-x
Helbok R, Kofler M, Schiefecker AJ, et al. Clinical use of cerebral microdialysis in patients with aneurysmal subarachnoid hemorrhage-state of the art. Front Neurol. 2017;8:565. doi:10.3389/fneur.2017.00565
doi: 10.3389/fneur.2017.00565
Ungerstedt U, Rostami E. Microdialysis in neurointensive care. Curr Pharm Des. 2004;10:2145–2152. doi:10.2174/1381612043384105
doi: 10.2174/1381612043384105
Hutchinson PJ, Jalloh I, Helmy A, et al. Consensus statement from the 2014 International Microdialysis Forum. Intensive Care Med. 2015;41:1517–1528. doi:10.1007/s00134-015-3930-y
doi: 10.1007/s00134-015-3930-y
Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005;22:3–41. doi:10.1089/neu.2005.22.3
doi: 10.1089/neu.2005.22.3
Van Landeghem FKH, Schreiber S, Unterberg AW, et al. Differential concentration-dependent effects of prolonged norepinephrine infusion on intraparenchymal hemorrhage and cortical contusion in brain-injured rats. J Neurotrauma. 2003;20:1327–1337. doi:10.1089/089771503322686120
doi: 10.1089/089771503322686120
Pfister D, Strebel SP, Steiner LA. Effects of catecholamines on cerebral blood vessels in patients with traumatic brain injury. Eur J Anaesthesiol Suppl. 2008;42:98–103. doi:10.1017/S0265021507003407
doi: 10.1017/S0265021507003407
Roberts RJ, Miano TA, Hammond DA, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med. 2020;48:1445–1453. doi:10.1097/CCM.0000000000004476
doi: 10.1097/CCM.0000000000004476
Rasulo FA, Girardini A, Lavinio A, et al. Are optimal cerebral perfusion pressure and cerebrovascular autoregulation related to long-term outcome in patients with aneurysmal subarachnoid hemorrhage? J Neurosurg Anesthesiol. 2012;24:3–8. doi:10.1097/ANA.0b013e318224030a
doi: 10.1097/ANA.0b013e318224030a
Soppi V, Kokki H, Koivisto T, et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage—a pilot study. Eur J Clin Pharmacol. 2007;63:355–361. doi:10.1007/s00228-007-0267-7
doi: 10.1007/s00228-007-0267-7
Abboud T, Andresen H, Koeppen J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2015;157:763–767. doi:10.1007/s00701-015-2369-9
doi: 10.1007/s00701-015-2369-9
Wolf S, Schürer L, Engel DC. Room air readings of brain tissue oxygenation probes. Acta Neurochir Suppl. 2018;126:197–199. doi:10.1007/978-3-319-65798-1_40
doi: 10.1007/978-3-319-65798-1_40